All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
MANIFEST-2 updated results: Pelabresib plus ruxolitinib in JAKi-naïve patients with MF
Bookmark this article
|
Pelabresib is an oral, small-molecule BET inhibitor capable of modifying critical components of MF pathobiology. Updated results from the MANIFEST-2 trial (NCT04603495) evaluating the long-term efficacy and safety of pelabresib + ruxolitinib vs ruxolitinib + placebo in JAKI-naïve patients with MF were presented by John Mascarenhas at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
| A higher proportion of patients receiving PELA + RUX arm achieved SVR35 responses at Week 48 vs those receiving RUX + PBO (57.0% vs 37.5%). |
| At Week 48, TSS50 responses were achieved by 45.3% vs 39.4% of patients receiving PELA + RUX vs RUX + PBO, respectively. Grade ≥1 BM fibrosis improvement was higher with PELA + RUX vs RUX + PBO (41.0% vs 15.0%). |
| Hb responses were achieved by 13.1% and 7.9% of patients receiving PELA + RUX vs RUX + PBO, respectively. Grade ≥3 anemia was reported in 25.9% vs 38.3% of patients in the PELA + RUX vs RUX + PBO arms, respectively. |
| These findings suggest that PELA + RUX results in deep and sustained responses and continues to improve outcomes in JAKi-naïve patients with MF. Longer-term follow-up results will be presented at future conferences. |
Abbreviations: ASH, American Society of Hematology; BET, bromodomain and extra-terminal; BM, bone marrow; Hb, hemoglobin; JAKi, Janus kinase inhibitor; MF, myelofibrosis; PELA, pelabresib; PBO, placebo; RUX, ruxolitinib; SVR35, spleen volume reduction ≥35%; TSS, total symptom score.
- Mascarenhas J. Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor–naïve patients with myelofibrosis. Poster #3178. Presented at: 66th ASH Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox